Can J Diabetes 2018;42:S316
"The two therapies may work best in combination, but we're still trying to figure out the best sequence and timing," he adds
In the phase 3 OASIS 1 trial published in The Lancet, participants taking higher-dose oral semaglutide lost an average of 15% of their body weight at 68 weeksrising to 17% among those who fully adhered to the protocol over that same period
Mounjaro and Vision Changes 2026 Update July 2026: There are currently 146 pending claims in the MDL for patients alleging that GLP-1 drugs, including Mounjaro, led them to develop NAION (vision loss)
Active -tocopherol can be regenerated by interaction with vitamin C following scavenge of a peroxy free radical
Genetic testing doesn't replace clinical judgment, but it does explain why some patients respond dramatically to GLP-1 therapy while others require dose adjustments or dual-compound protocols